Voriconazole 40mg/mL; pwd for reconstitution; orange flavor. Store at 2°C to 8°C (36°F to 46 F) in a refrigerator before reconstitution. The shelf-life is 24 months. The reconstituted suspension ...

NEW YORK, June 1, 2005 – Initial therapy with Pfizer's antifungal treatment, VFEND® (voriconazole), IV for injection, tablets, and oral suspension, has significant cost advantages over the standard ...

Voriconazole 200mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free. The primary mechanism of action of voriconazole is the inhibition of fungal cytochrome ...

Prague, Czech Republic, May 3, 2004 – Pfizer Inc's antifungal VFEND® (voriconazole) was shown to be as effective as a regimen of amphotericin B followed by fluconazole in the primary treatment of ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND ® (voriconazole) and ERAXIS ...

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...

PITTSBURGH, Feb. 15, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a ...

PITTSBURGH, Sept. 30, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the ...

Jan. 13, 2005 — The U.S. Food and Drug Administration (FDA) has approved an expanded indication for tositumomab therapy, allowing its use in a broader population of patients with non-Hodgkin's ...

New Delhi, Dec 19: Homegrown pharma major Lupin Ltd today announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infections in children.

Le groupe pharmaceutique américain Pfizer a annoncé aujourd’hui qu’il venait de conclure un accord avec deux filiales du génériqueur Mylan concernant la commercialisation d’une version générique de ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal ...